Saskia Neuteboom

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

Dharminder Chauhan, Laurence Catley, Guilan Li et al. · Cancer Cell · 2005 · 695 citations · Full text

Hematological Malignancy, Medicine, Apoptosis +9

NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent

Benjamin Nicholson, G. Kenneth Lloyd, Brian Miller et al. · Anti-Cancer Drugs · 2005 · 250 citations

Structure−Activity Relationship Studies of Salinosporamide A (NPI-0052), a Novel Marine Derived Proteasome Inhibitor

Venkat R. Macherla, Scott S. Mitchell, Rama Rao Manam et al. · Journal of Medicinal Chemistry · 2005 · 235 citations

Proteasome Inhibition, Medicinal Chemistry, Pharmaceutical Chemistry +14

Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia

John R. McWhirter, Saskia Neuteboom, Edward V. Wancewicz et al. · Proceedings of the National Academy of Sciences · 1999 · 154 citations

Hematological Malignancy, Cancer Research, Lymphoid Neoplasia +15

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

Michael Millward, Timothy Price, Amanda Townsend et al. · Investigational New Drugs · 2011 · 148 citations

Vitro Assessments, Oncology, Medicine +6